Lundbeck presents results from two studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders
Lundbeck advances its commitment to addressing the unmet needs of Multiple System Atrophy (MSA) with the TALISMAN study, adding to the encouraging results from the AMULET trial.H. Lundbeck A/S (Lundbeck) announces data from the TALISMAN natural history study, as well as additional data from the AMULET trial of amlenetug (Lu AF82422) in Multiple System Atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders (MDS congress) in Philadelphia, USA. The TALISMAN study is a step forward in Lundbeck’s commitment to understanding the course of MSA and developing